Myriad Genetic Screens & Tests

BRACAnalysis CDx product signature

BRACAnalysis CDx® is an FDA-approved test used to identify patients with germline BRCA1/2 mutations who may be eligible for certain targeted therapies.

  • For patients with breast, ovarian, pancreatic or prostate cancer
  • FDA approved, accurate germline BRCA1/2 testing to identify eligibility for targeted therapies
  • No family history is required to meet genetic testing guidelines
EndoPredict product signature
For patients with ER+, HER2-, node-negative or node-positive breast cancer, EndoPredict® provides three individualized results to use to help determine the right breast cancer treatment decisions.
Foresight® Carrier Screen product signature

Foresight® Carrier Screen detects a couple’s risk of passing down serious, inheritable health conditions to their child to guide informed planning and preparation.

  • Identify the 1 in 22 couples at risk for pregnancies with serious, prevalent, or clinically-actionable inherited conditions
  • 99% detection rate across ethnicities for the vast majority of the 176 genes on our panel2
GeneSight® Mental Health Medication Test product signature

The GeneSight® Psychotropic test analyzes how a patient’s genes may affect their outcomes with medications commonly prescribed to treat depression, anxiety, ADHD and other mental health conditions.

  • Delivers genetic insights that can help inform your mental health treatment plans
  • Access to test significantly improved remission and response rates compared to treatment as usual3
  • Ordered by tens of thousands of clinicians for 2MM+ patients
MyChoice® CDx product signature

For patients with ovarian cancer, MyChoice® CDx examines an ovarian cancer tumor’s HRD status to help determine whether a patient may be a candidate for PARP inhibitor therapy.

MyRisk™ product signature

MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

  • All-in-one personalized cancer risk assessment
  • Evaluates 48 genes associated with 11 different hereditary cancers
  • RiskScore® predicts a patient’s 5-year and lifetime risk of developing breast cancer
Precise™ Tumor product signature
Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Prequel®Prenatal Screen product signature

Designed for everyone regardless of ancestry and BMI or ability to pay, the Prequel® Prenatal Screen can determine if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as 10 weeks.

  • The only non-invasive prenatal screening (NIPS) that uses AMPLIFY™ technology
  • 99.9% result delivery on the first draw at 10 weeks1
  • Accessible and reliable for everybody, regardless of BMI, ancestry, or ability to pay
Prolaris® product signature

Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.

Illuminating the path to better health through genetic insights

Our tests and screens reveal information to guide patients and providers to better health and well-being. Whether you’re searching for answers related to cancer risk, cancer treatment, prenatal care or mental health, Myriad screens and tests can help.